Oisin Biotechnologies could be on the verge of cancer and antiaging breakthroughs

Clearing old “zombie” cells from the human body has been shown to extend the lives of mice.

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells.

Oisin Biotechnologies will start clinical trials testing senescent cell human trials should start in 2019 with the target of fighting cancer. These clinical trials will be to use repeated dosing of lipids with gene therapy to trigger cell death in cells that show P19 and other active genes.

Oisin has been able to repeatedly and safely apply gene therapy safely throughout the bodies of mice and monkeys.

Repeated dosing has been shown to reduce tumor size and control certain cancers in mouse models. They have tested repeated dosing in monkeys as well.

The phase 1 and phase 2 clinical trials will hopefully prove that the repeated dosing is safe and effective in humans.

In Canada, Oisin will be able to take cancer patients with any type of cancer. Oisin will proceed to later phases against the cancers which respond best to their treatments.

Repeated dosing to achieve antiaging breakthrough 5-year old mice

In the antiaging trials on mice, 90% 2-year-old mice that received one dose of the combination treatment survived to 2.5 years while only 50% of untreated mice survived.

If repeated dosing was as effective as the first 6 months then 53% of the mice might survive to 5 years of age. (0.9*0.9*0.9*0.9*0.9*0.9 = 0.53). This would mean the Antiaging Mouse prize would be won. The optimal dosing schedule to keep senescent cells cleared might be even more frequent than once every 6 months in mice. It might be once every month or two.

Aubrey de Grey and SENS have talked about robust mouse rejuvenation being the key milestone for antiaging. By 2021, we could know if Oisin Biotech can achieve it with repeated dosing of senescent cell clearing.